GlassScriptPhysician profile
Aaron Frederick Blair
NPI 1972094316
$1,630.37
in general payments reported to CMS, 2019-2025
25 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.85 · 2020: $25.76 · 2021: $274 · 2022: $483 · 2023: $228 · 2024: $371 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.41 | 2021-2025 | Vraylar, Linzess, Qulipta |
| Novo Nordisk INC | $205.21 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $203.55 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $180.29 | 2022-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $124.52 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.27 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $66.78 | 2022 | |
| Glaxosmithkline, LLC. | $58.63 | 2019-2022 | |
| Axsome Therapeutics, INC. | $58.08 | 2022-2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.81 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.15 | 2024 | Caplyta |
| Mylan Specialty L.P. | $30.37 | 2022-2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $29.24 | 2022 | |
| Globus Medical, INC. | $27.59 | 2025 | Senza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $24.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.78 | 2024 | Rexulti |
| Abbott Laboratories | $19.75 | 2024 | Freestyle Libre 3 |
| Corium, LLC | $19.63 | 2024 | Azstarys |
| Medtronic, INC. | $18.86 | 2022 | |
| Acadia Pharmaceuticals INC | $18.24 | 2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $16.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.94 | 2024 | |
| Exact Sciences Corporation | $13.28 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.